Testosterone and Long Pulse Stimulation After SCI
NCT03345576
Completed
Denervation following spinal cord injury (SCI) limits beneficial application of neuromuscular electrical stimulation (NMES). SCI with denervation results in extensive muscle atrophy that is accompanied with several cardio-metabolic health risks. The current proposal provides a novel intervention by examining the effects of long pulse width stimulation (LPWS) and testosterone replacement therapy (TRT) on restoring muscle size and leg lean mass after denervation in persons with SCI. This intervent... Read More
Gender:
MALE
Ages:
Between 18 years and 70 years
Trial Updated:
11/15/2024
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia
Conditions: Spinal Cord Injury
Register for Updates
An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD
NCT06082817
Not Yet Recruiting
This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Eligible subjects will receive 50 mg capsules of Kyzatrax® to be taken orally daily over a 3-month period. Multiple blood samples will be taken at baseline and on days 7, 28 and 56 to assess safety and pharmacokinetics of the testosterone. After the informed consent is signed and for up to 14 days after the last dose of study drug, participants will have serial blood samples collected in addition t... Read More
Gender:
FEMALE
Ages:
Between 21 years and 75 years
Trial Updated:
11/11/2024
Locations: San Diego Sexual Medicine, San Diego, California
Conditions: Hypoactive Sexual Desire Disorder
Register for Updates
Sipuleucel-T Combined with Bipolar Androgen Therapy in Men with MCRPC
NCT06100705
Recruiting
This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor which the activated autologous dendritic cells in the Sipuleucel-T vaccine are loaded with) in patients with metastatic castration resistant prostate ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
NCT03887936
Active Not Recruiting
Low testosterone and diabetes mellitus are each associated with increased risk for fractures. Men with diabetes mellitus are commonly found to have low testosterone as well. Testosterone has been shown to improve the bone health of patients with low testosterone but has not been tested in patients who also have diabetes mellitus in addition to low testosterone. To date, there is no treatment that is specifically recommended for bone disease among patients with diabetes. This study will evaluate... Read More
Gender:
MALE
Ages:
Between 35 years and 70 years
Trial Updated:
10/25/2024
Locations: Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas
Conditions: Type 2 Diabetes Mellitus, Hypogonadism
Register for Updates
Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
NCT04807894
Recruiting
Women over the age of 60 years have an estimated 10 to 15 % risk of recurrent urinary tract infections (UTI). This is believed to be due to hormonally induced changes in the vaginal flora associated with menopause. After menopause, there is a chemical changes in the vagina that may predispose to bacterial infections. The role of vaginal estrogen creams to restore vaginal atrophy and prevent urinary tract infections has been well characterized. Vaginal testosterone (VT) application use in postme... Read More
Gender:
FEMALE
Ages:
Between 60 years and 90 years
Trial Updated:
10/21/2024
Locations: Maimonides Medical Center, Brooklyn, New York
Conditions: Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
Register for Updates
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months
NCT06385509
Active Not Recruiting
TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
10/18/2024
Locations: Alliance for Multispecialty Research, Tempe, Arizona +26 locations
Conditions: Hypogonadism
Register for Updates
Cardiovascular Outcomes of Low Testosterone
NCT02758431
Completed
This study plans to learn more about heart and vascular aging in men. In some men as they get older, testosterone levels fall below the normal range for young men. Also, as men get older cardiovascular health worsens. This can lead to high blood pressure and heart disease. In this study we want to find out what causes cardiovascular health to worsen in older men. Also we want to find out what happens when testosterone levels are lowered for a short time. Specifically, we want to see if the reduc... Read More
Gender:
MALE
Ages:
Between 18 years and 75 years
Trial Updated:
10/07/2024
Locations: University of Colorado CCTSI CTRC, Denver, Colorado
Conditions: Hypogonadism
Register for Updates
Stereotactic Body Radiation Therapy in Treating Patients with Localized Prostate Cancer That Have Undergone Surgery
NCT03541850
Active Not Recruiting
This phase II trial studies how well stereotactic body radiation therapy works in treating patients with prostate cancer that has not spread to other parts of the body and have undergone surgery. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/12/2024
Locations: USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, California +1 locations
Conditions: PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Register for Updates
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
NCT00080756
Active Not Recruiting
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Deslorelin combined with low-dose add-back estradiol and testosterone (given to replace hormones suppressed by deslorelin) may be effective in preventing breast cancer in at-risk women. PURPOSE: This phase II trial is studying how well giving deslorelin together with estradiol and testosterone works in preventing breast cancer in premenopausal women who are at high risk for... Read More
Gender:
FEMALE
Ages:
Between 21 years and 48 years
Trial Updated:
08/26/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Register for Updates
Testosterone Replacement Therapy in Advanced Chronic Kidney Disease
NCT00645658
Completed
Muscle wasting is common in advanced chronic kidney disease (CKD) and adversely affects morbidity and mortality. In 2/3 of males with advanced CKD serum testosterone (TT) levels are reduced, and likely contributes to the wasting. As TT in relatively safe physiologic replacement doses, increases muscle mass in otherwise normal TT deficient subjects, we hypothesize that physiologic TT replacement will be effective in preventing and treating the loss of muscle mass and function in CKD patients, wil... Read More
Gender:
MALE
Ages:
Between 45 years and 80 years
Trial Updated:
07/31/2024
Locations: VA Palo Alto Health Care System, Palo Alto, California +1 locations
Conditions: Kidney Failure, Kidney Diseases
Register for Updates
The Influence of Testosterone on Experimental Pain Perception
NCT05781685
Completed
This trial examined how the administration of exogenous testosterone would influence pain tolerance and other endogenous steroids (i.e. estradiol and progesterone).
Gender:
FEMALE
Ages:
Between 18 years and 25 years
Trial Updated:
07/10/2024
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Acute Pain
Register for Updates
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
NCT06244004
Recruiting
This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate cancer that is sensitive to androgen-deprivation therapy (ADT) and has spread from where it first started (primary site) to other places in the body (metastatic). Prostate cancer is the second leading cause of cancer death among men in the United States, despite... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/08/2024
Locations: Northwestern University, Chicago, Illinois +4 locations
Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates